Boston Scientific Enters into a Definitive Agreement to Acquire SoniVie for $600M
Shots:
- Boston Scientific entered into a definitive agreement to acquire SoniVie Ltd. to expand its interventional cardiology therapies offerings
- Currently, the company holds an equity stake of approx. 10%, and for the remaining 90% stake, the company will pay approx. $360M upfront and up to $180M regulatory milestones; for 100% stake, the amount sums up to $400M upfront and $200M regulatory milestone; transaction completion is expected in H1’25
- TIVUS Intravascular Ultrasound System is the lead asset of the company that is an investigational device developed to treat a variety of hypertensive disorders, incl. renal artery denervation, and currently the device is being investigated in THRIVE global IDE pivotal trial
Ref: Boston Scientific | Image: SoniVie
Related News:- The US FDA Grants Approval to Boston Scientific’s Farapulse Pulsed Field Ablation (PFA) System for Atrial Fibrillation (AF)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
An avid reader and a dedicated learner, Prince works as a Content Writer at PharmaShots. Prince possesses an exceptional quality of breaking down the barriers of words by simplifying the terms in digestible chunks to make content readable and comprehensible. Prince likes to read books and loves to spend his free time learning and upskilling himself.
